Company intelligence / Profile preview

LDH

Ownership: Private
Development stage: Other

Overview

LDH is a biotechnology company focused on the development of novel small molecule inhibitors targeting lactate dehydrogenase (LDH) enzymes, specifically LDHA and LDHB. The company's research centers on the Warburg effect, aiming to disrupt the metabolic pathways that cancer cells rely on for rapid growth and survival. By inhibiting LDH, the company seeks to reduce lactate production and restore normal cellular metabolism, potentially offering a new therapeutic approach for various solid tumors. LDH is currently in the pre-clinical stage, advancing its lead candidates through optimization and early validation studies.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on LDH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDH.

Explore the full profile